- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04443088
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 1a: it is anticipated that approximately 36 patients will be enrolled in the dose escalation phase as a single agent of the study. Additionally, up to 9 additional patients may be enrolled to confirm the safety of patients treated at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
Phase 1b: approximately 36-42 patients will be enrolled in the dose escalation and de-escalation phases in the combination with pembrolizumab. One or more combination dose levels that could represent the combination RP2D will be expanded to a total of 12-15 patients to confirm safety and tolerability of the combination.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: radhika Shah, MD
- Phone Number: 1 984 459 5523
- Email: radhika.shah@syneoshealth.com
Study Locations
-
-
Indiana
-
Lafayette, Indiana, United States, 47905
- Recruiting
- Horizon Oncology Research, LLC,
-
Principal Investigator:
- Costantine Albany, MD
-
Contact:
- Karyn Burnworth
- Phone Number: 765-446-5111
- Email: kburnworth@verdioncology.com
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- START
-
Contact:
- Angela Galindo
- Email: Angela.Galindo@startthecure.com
-
Principal Investigator:
- Amita Patnaik, MD
-
San Antonio, Texas, United States, 78229
- Recruiting
- UT Health
-
Principal Investigator:
- John Sarantopoulos, MD
-
Contact:
- Karla Hagerty
- Phone Number: 210-450-1920
- Email: hagertyk@uthscsa.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent, according to local guidelines, signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses;
- Patient must be ≥18 years-of-age at the time of signature of the informed consent form (ICF);
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1;
- Patients with histologically or cytologically confirmed advanced solid tumors which have progressed on or following standard therapy or for which no standard therapy exists;
- Patients with life expectancy ≥3 months;
- Patients with at least one measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), according to RECIST v1.1. Tumor lesions that have been irradiated ≥4 weeks before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions in the absence of measurable lesions that have not been irradiated;
- Patients whose laboratory data at screening meet the acceptable criteria for bone marrow, liver function and renal function.
- Women of childbearing potential (WOCBP) must have a negative urine pregnancy test during screening. A woman is considered of childbearing potential (fertile) following menarche and until becoming postmenopausal unless permanently sterile. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Postmenopausal women can be included;
Male patients with female partners of childbearing potential and female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 3 months following last dose. Medically acceptable contraception includes:
- Hormonal methods (Needs to have been instituted at least 1 month prior to the first dose of study drug):
- Barrier methods:
- Abstinence, defined as refraining from sexual intercourse
- Male patients must also refrain from donating sperm from the first dose of study drug until 4 months after the last dose of study drug;
- Patients must be able to swallow and retain orally administered medication.
Exclusion Criteria:
- History (≤5 years) or current evidence of cancer that is histologically distinct from the cancer under study, except for cervical carcinoma in situ, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer. Patients with hepatocellular carcinoma will be excluded from Phase 1b dose escalation;
- Known serious allergy to investigational drug or excipients (microcrystalline cellulose);
- History of severe autoimmune disease (including significant ongoing immune-related adverse events of prior immune-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone >10 mg/day or equivalent);
- Known malignant central nervous system disease other than neurologically stable, treated brain metastases - defined as metastases having been treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of progression or hemorrhage and off any systemic corticosteroids for at least 4 weeks prior to signing the consent;
- History (within 4 weeks of starting treatment) or evidence of active infections (Grade ≥2);
- Seropositive status for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at any time before the start of treatment: Testing for seropositive status during screening will be at the discretion of the Investigator in patients without previously reported results;
- History or evidence of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study, such as any disorder or surgical procedure that could impact the absorption of study drug from the gastrointestinal tract.
- History (≤6 months before the start of treatment) or evidence of any of the following: acute myocardial infarction, unstable angina pectoris, coronary artery bypass graft, cerebrovascular accident, or transient ischemic attack;
Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- Congenital long QT syndrome;
- Significant ventricular or supraventricular arrhythmias (patients with sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible);
- LVEF < 50% by ECHO or MUGA;
- Other clinically significant heart disease such as known congestive heart failure New York Heart Association (NYHA) Class III-IV;
- Patients with QT interval ≥470 msec in females and ≥450 msec in males at screening using Fridericia's formula (determined as the mean of 3 QTcF values from the screening triplicate ECG obtained with adequate quality);
- Women who are pregnant or breastfeeding.
- WOCBP and sexually active fertile men with WOCBP partners who are unwilling or unable to use acceptable contraception method to avoid pregnancy for at least 1 month before the first dose of the study drug, during the study, and for 4 months after the last dose of study drug;
- Male patient who plans to father a child while enrolled in this study or within 4 months after the last dose of study drug;
- Not recovered from toxicity from prior anticancer therapy to baseline or Grade 1 (except toxicities which are not clinically significant such as alopecia, skin discoloration).
- History of an allogeneic bone marrow or solid organ transplant;
- Use of systemic anti-cancer agent (except luteinizing hormone-releasing hormone (LHRH) agonists, bisphosphonates and denosumab) or investigational drug ≤28 days or five half-lives whichever is shorter prior to the first dose of study treatment;
- Radiation therapy ≤28 days prior to the first dose of study treatment, or likely to require radiation therapy at any time until the 30 days after the last dose of study treatment, except for palliative radiation therapy limited to non-target bone lesions;
- Major surgery within 4 weeks before enrollment or surgery with ongoing post-operative complications);
- History of transfusion of platelets ≤2 weeks before the start of treatment;
- Patients who start erythropoietin or granulocyte-colony stimulating factor (G-CSF), pegfilgrastim, or filgrastim ≤3 weeks before screening;
- Patients taking medications known to have a significant risk of causing Torsades de Pointes. Patients who have discontinued any of these medications must have a wash-out period of at least 7 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug.
- History of use of H2 blockers (<24 hours before the first dose of study treatment and during the study) and proton pump inhibitors (<5 days before the first dose of study treatment and during the study).
Patients with recent (within past 12 months) history, or are currently being treated for gastroesophageal ulcer.
The following additional exclusion criteria will apply to patients enrolling in Phase 1b:
- Have been discontinued treatment due to a Grade 3 or higher immune-related (irAE) from prior anti-PD-1 or anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) (only for dose expansion).
- Patient is currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of administration of investigational products.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease or radiation pneumonitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Dose Escalation
Phase 1a: Subjects will receive escalating doses of INV-1120 orally once a day until un-acceptable toxicity or disease progression. Three to six patients will be enrolled per cohort to evaluate the safety and pharmacokinetics for each dose level. After the last patient in each cohort completes Cycle 1 (DLT observation period of 28 days), the Safety Evaluation Team (SET) will evaluate the safety data and pharmacokinetic collected from Cycle 1, and make the decision whether to escalate the dose before opening the second cohort. Phase 1b: Subjects will receive escalating and de-escalating doses of INV-1120 orally once a day in combination with pembrolizumab until un-acceptable toxicity or disease progression, and DLT observation period of 21 days. |
INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Determine DLTs and RP2Ds in INV-1120
Time Frame: 12 months
|
To evaluate dose limiting toxicities (DLTs) of INV-1120 in patients with advanced cancer and to establish a recommended Phase 2 dose (RP2D)
|
12 months
|
Phase 1b: Determine RP2D and DLTs of the combination of INV-1120 and pembrolizumab
Time Frame: 12 months
|
To determine RP2D, and to assess DLT of the combination of INV-1120 and pembrolizumab administered to adult patients with advanced solid tumors.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Determine the PK using AUC of INV-1120
Time Frame: 12 months
|
To determine the pharmacokinetics (PK) using AUC of INV-1120 after a single dose and at steady state after multiple doses
|
12 months
|
Phase 1b: Determine the PK using AUC of INV-1120
Time Frame: 12 months
|
To determine the pharmacokinetics (PK) using AUC of INV-1120 after a single dose and at steady state after multiple doses in combination with pembrolizumab
|
12 months
|
Phase 1a: Determine the PK using Cmax of INV-1120
Time Frame: 12 months
|
To determine the pharmacokinetics (PK) using Cmax of INV-1120 after a single dose and at steady state after multiple doses
|
12 months
|
Phase 1b: Determine the PK using Cmax of INV-1120
Time Frame: 12 months
|
To determine the pharmacokinetics (PK) using Cmax of INV-1120 after a single dose and at steady state after multiple doses in combination with pembrolizumab
|
12 months
|
Characterize investigator defined response overall response rate (ORR) etc using RECIST v1.1
Time Frame: 12 months
|
To characterize Investigator defined ORR, PFS and DOR using RECIST v1.1
|
12 months
|
Phase 1a: Characterize the safety of INV-1120 as assessed by CTCAE v5.0
Time Frame: 12 months
|
To analyze the safety profile of INV-1120 as a single agent by AE, clinical lab test results, ECG and Vital signs changes
|
12 months
|
Phase 1b: Characterize the safety of the combination of INV-1120 and pembrolizumab as assessed by CTCAE v5.0
Time Frame: 12 months
|
To analyze the safety profile of the combination of INV-1120 and pembrolizumab by AE, clinical lab test results, ECG and Vital signs changes
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1a: Characterize investigator defined ORR using iRECIST
Time Frame: 12 months
|
To characterize investigator defined ORR using iRECIST
|
12 months
|
Phase 1a: Characterize investigator defined PFS using iRECIST
Time Frame: 12 months
|
To characterize investigator defined PFS using iRECIST
|
12 months
|
Phase 1a: Characterize investigator defined DOR using iRECIST
Time Frame: 12 months
|
To characterize investigator defined DOR using iRECIST
|
12 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INV-1120-101(MK3475-E12)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on INV-1120
-
Innovo Therapeutics, Inc.Recruiting
-
Innovo Therapeutics, Inc.Completed
-
Inversago Pharma Inc.Active, not recruitingObesity | Metabolic SyndromeCanada
-
Inversago Pharma Inc.Completed
-
Inversago Pharma Inc.Completed
-
Inversago Pharma Inc.Worldwide Clinical TrialsRecruitingDiabetic Kidney DiseaseIsrael, United States, Mexico, Hungary, Georgia, Serbia, Canada
-
Boehringer IngelheimTerminatedCarcinoma, Non-Small-Cell LungJapan
-
Invirsa, Inc.RecruitingDry Eye DiseaseUnited States
-
Invirsa, Inc.Biomedical Advanced Research and Development AuthorityCompletedDry Eye DiseaseUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States